Teva’s 'Key Ingredient' For Growth: Biosimilars
Executive Summary
Teva has conducted due diligence on 36 biosimilar companies with the aim of signing a partner soon to fill a critical gap in its generics pipeline.
You may also be interested in...
Teva Embarks On New Phase With FTC Clearance Of Allergan Generics
Teva said the deal will close the first week of August, after agreeing to sell assets related to 79 pharmaceutical products to gain FTC clearance.
Teva CEO Vigodman Reveals A First Glimpse At His Strategy
Teva’s new CEO addressed investors publicly for the first time May 1 and discussed his initial thoughts on plans to turn around the generic drug leader. Those include deeper cost cuts, a renewed emphasis on generic drugs and biosimilars, and potentially a large acquisition.
Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain
Teva is the first company to get FDA approval of a version of Amgen’s Neupogen; one biosimilar expert questions why Teva did not switch its BLA to a biosimilar application when that pathway became available.